Tag: ESMO Congress

Browse exclusive Tags!

Selpercatinib Outperforms Competitors in Treating RET-Mutant Thyroid Cancer, France

Discover the promising results of selpercatinib, a kinase inhibitor by Eli Lilly, in treating RET-mutant medullary thyroid cancer. Outperforms competitors with improved outcomes and longer progression-free survival.

Popular

Subscribe

spot_imgspot_img